Library - Rayner : Peer 2 Peer

Gain invaluable insights from leading ophthalmic surgeons around the world.

OMIDRIA Special - Innovations in Dropless Cataract Surgery Solutions

OMIDRIA Special - OMIDRIA Pearls from AECOS 2023

OMIDRIA Special - From Trial to OMIDRIA on board for Every Surgery: Experts Share Why

OMIDRIA Special - Performance and Clinical Outcomes of OMIDRIA in Cataract Surgery

OMIDRIA Special - Using OMIDRIA for Mitigating Risk in Cataract Surgery

OMIDRIA Special - An OMIDRIA Overview

OMIDRIA benefits you and your patients
Dr Walter

IFIS – Risk Patient

Patients At-Risk of IFIS
Dr Silverstein

Dropless Strategies with OMIDRIA
Dr McCabe & Dr Singh

OMIDRIA’s intra-and postoperative experience
Dr Wiley & Dr Hura

Modern Solution for Modern Cataract Surgery
Dr Endl

OMIDRIA: Evolving the Landscape
Dr Donnenfeld

Elevating Cataract Surgery Efficiency and Outcomes
Dr Sturbaum

Unlocking Better Outcomes
Dr Stonecipher

Enhancing Patient Comfort and Surgeon’s Ease in Cataract Surgery
Dr Kontos

Key Factors for Successful Cataract Surgery
Dr Katsev

Optimizing Cataract Surgery Outcomes
Dr Bucci

Mitigating Challenges and Optimizing Cataract Surgery
Dr Olsen

OMIDRIA: Shattering Boundaries
Dr Donaldson

Enhancing Patient Experience: The Impact of OMIDRIA in Cataract Surgery
Dr Nikpoor

Minimizing Unexpected Events for Better Outcomes
Dr McCabe

Predictability and Simplicity: Dr. Greenwood’s OMIDRIA Story
Dr Greenwood

OMIDRIA: Redefining Postoperative Comfort
Dr Foster

8 Years with OMIDRIA: Simplifying Surgery
Dr Jackson

Dr. Singh on Cataract Surgery Insights
Dr Singh

Why Use OMIDRIA?

OMIDRIA: A Dual Perspective
Dr Wagle & ASC Administrator Heather Higendorf-Cooley

One Solution, Many Applications
Dr McCabe & Dr Shamie

More than meets the eye
Dr McCabe & Dr Shamie

Taking the OMIDRIA surgical day challenge
Dr McCabe & Dr Shamie

OMIDRIA Exceeds Expectations
Dr Metzinger

OMIDRIA’s Effect on Intra and Post Operative Complications
Dr Metzinger

Steroid Sparing Experience
Dr Metzinger

See why Drs. Wiley and Hura started using OMIDRIA
Dr Wiley & Dr Hura

The Proof Is in the Post-Op
Dr Wiley & Dr Hura

One Vial, Lasting Effects
Dr Wiley & Dr Hura

Interaoperative Miosis is Unpredicatable

Hyperopia + Tamsulosin
Dr Singh

Dr. Visco shares how OMIDRIA can benefit your practice
Dr Visco

The impact of pupillary miosis on cataract surgery
Dr Silverstein

Drs. Visco And Walter discuss OMIDRIA study results
Dr Visco & Dr Walter

Why I Choose OMIDRIA
Dr Walter

Hear Dr. Silverstein share OMIDRIA study results
Dr Silverstein

Delivering a Dropless Pathway in Cataract Surgery

Kourtney Houser and John Hovanesian discuss how dropless therapy regimens with OMIDRIA® equal – and...

Blocking the Inflammatory Cascade

Dr. Donnenfeld sheds light on the myriad of benefits of integrating OMIDRIA in cataract...

Making Cataract Surgery Child’s Play

Dr. Wilson shares his study results demonstrating that OMIDRIA is safe for use in...

Controlling postoperative inflammation and associated complications with OMIDRIA

Dr. Visco discusses the surgical and patient benefits of continuous intracameral administration of OMIDRIA.

Effects of OMIDRIA on postoperative CME, iritis, pain, and photophobia

This retrospective study shows that patients receiving OMIDRIA and topical NSAID without postoperative topical...

The role of non-opioid alternatives in cataract surgery pain management

This retrospective study demonstrated a reduction in the quantity of opioids prescribed for patients...

Pain control and reduction of opioid use with OMIDRIA

This prospective study demonstrated that patients treated with OMIDRIA had a statistically significant lower...

IMPORTANT SAFETY INFORMATION

OMIDRIA must be added to irrigating solution prior to intraocular use.

OMIDRIA is contraindicated in patients with a known hypersensitivity to any of its ingredients.

Systemic exposure to phenylephrine may cause elevations in blood pressure.

Use OMIDRIA with caution in individuals who have previously exhibited sensitivities to acetylsalicylic acid, phenylacetic acid derivatives, and other nonsteroidal anti-inflammatory drugs (NSAIDs), or have a past medical history of asthma.

The most commonly reported adverse reactions at ≥ 2% are eye irritation, posterior capsule opacification, increased intraocular pressure, and anterior chamber inflammation.

You are encouraged to report Suspected Adverse Reactions to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Podcasts

Videos

Publications / white papers